Serious Adverse Events After Mectizan Treatment for Onchocerciasis
Author Information
Author(s): Brian Duke, Michael J Brown
Primary Institution: River Blindness Foundation
Hypothesis
What are the risks and management strategies for serious adverse events following Mectizan treatment in areas co-endemic for Loa loa?
Conclusion
The report emphasizes the need for careful management and education regarding the risks of Loa-encephalopathy following Mectizan treatment.
Supporting Evidence
- 65 cases of Loa-encephalopathy were temporally related to Mectizan treatment.
- 85% of the cases were in males.
- 93% of cases followed the first dose of ivermectin.
- 97% of cases were reported from Cameroon.
- The mean time to onset of symptoms was 1.7 days.
Takeaway
This study looks at the risks of a serious brain condition that can happen after taking a medicine for river blindness, especially in certain areas.
Methodology
The report reviews data from past reports and discusses the risks associated with Mectizan treatment in co-endemic areas.
Potential Biases
Potential bias in reporting cases due to differences in healthcare access in various regions.
Limitations
The exact pathogenesis of Loa-encephalopathy is not fully understood, and the report relies on historical data.
Participant Demographics
Among the 207 cases, 85% were male, and the mean age was 39.9 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website